🔗 Permalink

Inventor profile of:

Ingrid Teige

City:

Lund

Country:

Sweden

Published Applications:

Last publication date:

2026-04-30

Top Assignees for applications by Ingrid Teige

The entities that hold a legal rights for patent applications filed by inventor Teige Ingrid:

BIOINVENT INTERNATIONAL AB 10 Lund, Sweden
UNIVERSITY OF SOUTHAMPTON 4 Southampton, United Kingdom
KANCERA AB 2 Solna, Sweden
TRANSGENE S.A. 1 Illkirch Graffenstaden Cedex, France
Cancer Research Technology Limited 1 London, United Kingdom
BIOVENT INTERNATIONAL AB 1 Lund, Sweden

Recent patent applications by Teige Ingrid

Ingrid Teige from Lund, SE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-04-30

US20260116981A1

Chemistry; metallurgy

NOVEL COMBINATION AND USE OF ANTIBODIES

#2 | 2026-04-30

US20260115286A1

Human necessities

COMBINED USE OF FC GAMMA RIIB (CD32B) AND CD20 SPECIFIC ANTIBODIES

#3 | 2026-01-01

US20260001958A1

Chemistry; metallurgy

MEDICAMENTS, USES AND METHODS

#4 | 2025-12-25

US20250388690A1

Chemistry; metallurgy

NOVEL ANTAGONISTIC ANTI-TNFR2 ANTIBODIES

#5 | 2025-10-23

US20250326849A1

Chemistry; metallurgy

COMBINATION OF A FcyRIIB- AND A TUMOR ANTIBODY FOR USE IN THE TREATMENT OF AN FcyRIIB-NEGATIVE CANCER

#6 | 2025-08-14

US20250257135A1

Chemistry; metallurgy

NOVEL ANTIBODIES AND NUCLEOTIDE SEQUENCES, AND USES THEREOF

#7 | 2025-02-27

US20250066492A1

Chemistry; metallurgy

AGONISTIC ANTI TNFR2 ANTIBODY MOLECULES

#8 | 2024-09-12

US20240301070A1

Chemistry; metallurgy

IMPROVING ANTIBODY TOLERABILITY ASSOCIATED WITH INTRAVENOUS ADMINISTRATION

#9 | 2024-03-21

US20240092912A1

Chemistry; metallurgy

NOVEL COMBINATIONS OF ANTIBODIES AND USES THEREOF

#10 | 2023-11-30

US20230381310A1

Human necessities

COMBINED USE OF FC GAMMA RIIB (CD32B) AND CD20 SPECIFIC ANTIBODIES

#11 | 2023-10-12

US20230322933A1

Chemistry; metallurgy

MODEL FOR PREDICTION OF TOLERABILITY ISSUES IN CONNECTION WITH INTRAVENOUS ADMINISTRATION OF THERAPEUTIC ANTIBODIES

#12 | 2023-02-23

US20230058227A1

Chemistry; metallurgy

NOVEL ANTIBODIES AND COMBINED USE OF A TREG DEPLETING ANTIBODY AND AN IMMUNOSTIMULATORY ANTIBODY

#13 | 2022-08-18

US20220259309A1

Chemistry; metallurgy

ANTIBODY COMBINATIONS FOR TREATMENT OF CANCER IN SPECIFIC PATIENTS

#14 | 2022-03-10

US20220073634A1

Chemistry; metallurgy

NOVEL AGONISTIC ANTI TNFR2 ANTIBODY MOLECULES

#15 | 2022-02-10

US20220041723A1

Chemistry; metallurgy

Antibodies and nucleotide sequences, and uses thereof

#16 | 2022-01-06

US20220002426A1

Chemistry; metallurgy

Agonistic anti TNFR2 antibody molecules

#17 | 2021-11-11

US20210346498A1

Human necessities

COMBINED USE OF FC GAMMA RIIB (CD32B) AND CD20 SPECIFIC ANTIBODIES

#18 | 2020-11-19

US20200362036A1

Chemistry; metallurgy

NOVEL COMBINATION AND USE OF ANTIBODIES

#19 | 2020-07-02

US20200207855A1

Chemistry; metallurgy

Combination of a Treg depleting anti-4-1BB antibody and anti-PD1 antibody

#20 | 2020-03-05

US20200069798A1

Human necessities

Combined use of FcγRIIb (CD32B) and CD20 specific antibodies

#21 | 2017-04-20

US20170107293A1

Chemistry; metallurgy

MEDICAMENTS, USES AND METHODS

#22 | 2014-10-23

US20140314793A1

Chemistry; metallurgy

Biological materials and uses thereof

#23 | 2014-01-02

US20140004156A1

Chemistry; metallurgy

Biological inhibitors of ROR1 capable of inducing cell death

#24 | 2013-10-24

US20130281922A1

Chemistry; metallurgy

Antibodies against ROR1 and uses thereof

#25 | 2013-09-26

US20130251706A1

Human necessities

Combined use of Fc gamma RIIb (CD32B) and CD20-specific antibodies

InventorID:

455119 ⎘